WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here
Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2824
[post_author] => 4
[post_date] => 2017-09-20 13:41:33
[post_date_gmt] => 2017-09-20 13:41:33
[post_content] => Avanti Biosciences, Inc. a preclinical-stage biopharmaceutical company lead by Center for Biotechnology BioEntrepreneur-in-Residence Dr. Gian Luca Araldi, has announced that the National Institute of Aging (NIA) has awarded the Company an SBIR fast-track grant of up to $1,930,000 to support the company’s small molecule treatment for Alzheimer’s disease (AD) over the next 3 years.
The award will enable the preparation and testing of Avanti’s proprietary compounds derivatized from natural catechins, which inhibit DYRK1A, an enzyme that modulates tau phosphorylation. Working with NY Institute for Basic Research and the University of California San Diego (UCSD), the company hopes to attenuate and potentially reverse pathogenesis for Alzheimer’s disease and other neurodegenerative diseases.
“This award marks a significant milestone for Avanti Biosciences and an important step for their research into a treatment for Alzheimer’s disease” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. “The Center for Biotechnology is thrilled to see another success for one of the emerging bioscience companies fueling our regional bioecosystem and we proudly support Dr. Araldi’s work as one of our BioEntrepreneurs-in-Residence.”
Dr. Gian Luca Araldi, Founder and Chief Executive Officer of Avanti, stated, “We are delighted to have been granted this funding from the NIA as it underscores the great need for innovative, effective treatments for this disease, and recognizes the potential benefits that our compounds may provide for patients with AD. The continuous support of Center for Biotechnology and the BioEntrepreneur-in-Residence program has been critical force in the development of our technology and the company as whole.”
More than five million people in the United States are living with Alzheimer’s disease, a progressive, irreversible, neurodegenerative disease that destroys memory and other cognitive abilities. It is the sixth leading cause of death in the United States and as the aging population in the country grows, the incidence rate is expected to rise dramatically.
Learn more about Avanti Biosciences: avantibiosciences.com
[post_title] => CFB BEIR Receives $1.9M SBIR Fast-Track
[post_excerpt] => Avanti Biosciences, Inc. a preclinical-stage biopharmaceutical company lead by CFB BioEntrepreneur-in-Residence Dr. Gian Luca Araldi, has announced that the National Institute of Aging (NIA) has awarded the Company an SBIR fast-track grant of up to $1,930,000 to support the company’s small molecule Alzheimer’s disease (AD) over the next 3 years.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => cfb-beir-receives-1-9m-sbir-fast-track
[to_ping] =>
[pinged] =>
[post_modified] => 2018-01-23 14:39:07
[post_modified_gmt] => 2018-01-23 14:39:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2824
[menu_order] => 138
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2039
[post_author] => 3
[post_date] => 2016-03-24 18:53:40
[post_date_gmt] => 2016-03-24 18:53:40
[post_content] => News 12 Long Island Recently highlighted Katarzyna Sawicka, Founder and President of ImmunoMatrix, a Stony Brook start-up and CFB client developing a technology that can deliver medication directly through the skin, no needles necessary. View the segment here.
[post_title] => “No More Needles” – News 12 LI Features ImmunoMatrix
[post_excerpt] => News 12 Long Island Recently highlighted Katarzyna Sawicka, Founder and President of ImmunoMatrix, a Stony Brook start-up and CFB client developing a technology that can deliver medication directly through the skin, no needles necessary.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => no-more-needles-news-12-li-features-immunomatrix
[to_ping] =>
[pinged] =>
[post_modified] => 2016-03-29 20:30:02
[post_modified_gmt] => 2016-03-29 20:30:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2039
[menu_order] => 187
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 1450
[post_author] => 3
[post_date] => 2015-03-12 16:15:37
[post_date_gmt] => 2015-03-12 16:15:37
[post_content] => Symbiotic Health, Inc, a New York City based company and Center for Biotechnology client, was named "Best in Show" at the first of MABA's 1st Pitch Life Science events in 2015, Symbiotic Health has developed a capsule to help kill Clostridium difficile (Cdiff) infection which causes severe, debilitating diarrhea, is the most frequent hospital-acquired infection in the US and an immediate public health threat that requires urgent and immediate action (CDC). The company's pipeline includes a capsule microbiome therapeutic designed to cure Cdiff by restoring a community of protective bacteria.
Dr. Gerard Honig, CEO of Symbiotic Health, presented on behalf of the company. Stephen M. Goodman, Co-founder of Mid Atlantic Bio Angels and a partner at Pryor Cashman LLP in New York City, also a panelist at the event said Dr. Honig's pitch and responses to questions demonstrated both mastery of the competitive space and a willingness to address challenges to his analysis calmly and directly. His style, as well as his substance, exemplified the maxim that it's not just the business plan but the management that ultimately brings a company success. Read more about the company and the competition here.
[post_title] => Symbiotic Health Wins Best in Show at 1st Pitch Competition
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => symbiotic-health-wins-best-in-show-at-1st-pitch-competition
[to_ping] =>
[pinged] =>
[post_modified] => 2016-03-02 17:58:26
[post_modified_gmt] => 2016-03-02 17:58:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1450
[menu_order] => 211
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here
Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 287
[max_num_pages] => 96
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] =>
)